Testosterone extended-release - GlaxoSmithKline

Drug Profile

Testosterone extended-release - GlaxoSmithKline

Alternative Names: T-8 oral testosterone - GlaxoSmithKline; Testosterone-extended-release

Latest Information Update: 03 Sep 2013

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; University of Washington
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Eye disorder therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Androgen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hypogonadism

Most Recent Events

  • 23 Jan 2015 Biomarkers information updated
  • 01 Jun 2012 GlaxoSmithKline completes a phase I trial in volunteers in USA (NCT01167829)
  • 27 Oct 2010 GlaxoSmithKline completes enrolment in a phase I trial in volunteers in USA (NCT01167829)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top